A day before he was convicted of securities fraud, "Pharma Bro" Martin Shkreli's presence was being felt as the Senate passed a bill targeting the price-gouging that made him infamous.

The former pharmaceutical CEO's move two years ago to raise the price of an anti-malarial drug called Daraprim by 5,000 percent overnight enraged the country. Experts say it also helped shed light on a particular brand of price gouging in the pharmaceutical industry.

"He is the person that keeps on giving for pharmaceutical reform," said W. Gerard Anderson, professor of health policy and management at the Johns Hopkins University Bloomberg School of Public Health. "Many of the things that he made visible we have developed legislative fixes, so the next person can't do it."

Anderson said Shkreli's actions as CEO of Turing Pharmaceuticals helped highlight a practice used by some companies to acquire older drugs that have been off patent for decades and then raise the price. Those drugs have little to no competition because not enough patients use them, making the price hikes easy as companies didn't want to go through an approval process of a year or more by the Food and Drug Administration.

Before Shkreli, there were instances of major increases of off-patent drugs, such as notably insulin, Anderson said.

"But Martin Shkreli was the person who raised [a drug price] 5,000 percent," he said. "By his antics, he has gotten everybody's attention."

Anderson noted that Maryland passed an anti-price gouging law this year and several regulatory fixes have been made to speed up approvals to foster greater competition to head off the practice.

The group Campaign for Sustainable Rx Prices noted that more work still needs to be done on drug pricing. While some moves have been made to boost generic competition, some wholesale reforms such as giving Medicare the power to negotiate lower drug prices remain in limbo.

"The fascination and outrage generated by the Shkreli trial demonstrates beyond a shadow of a doubt that Americans still care deeply about out-of-control prescription drug prices," spokesman Will Holley said. "And the fact that Daraprim is still $750 demonstrates beyond a shadow of a doubt that there is still much work for Congress and the administration to do in order to put an end to Big Pharma's price gouging."

On Thursday, the Senate passed an FDA funding package that included a provision to speed up approval of generic drugs. The provision sponsored by Sens. Susan Collins, R-Maine, and Claire McCaskill, D-Mo., lets the FDA hasten the approval of a generic version of a drug that has limited or no competition.

The FDA could approve a generic drug as quickly as eight months as opposed to the normal 10 months. President Trump is believed to sign the funding package into law.

Collins said the provision targeted "hedge fund pharmas" that wait "until the patent has expired and then buy the pharmaceutical drug and virtually overnight impose egregious price increases."

Shkreli helmed a hedge fund before leading several biotech companies.

The securities fraud charges he was convicted of didn't have anything to do with the Daraprim price hike, but were related to his time at the hedge fund. Shkreli was charged with using money from his hedge fund to prop up a pharmaceutical company called Retrophin.

But he rocketed to infamy as the CEO of Turing Pharmaceuticals, which acquired the antimalarial drug Daraprim in 2015 for $55 million.

The drug, used to treat a parasite, had been on the market for decades but had no competition because it had a limited patient population.

Turing raised the price practically overnight from $13.50 to $750 a pill.

Instead of shrinking from the negative press after the increase came to light, Shkreli was defiant.

He once told a group of pharmaceutical executives that he would have raised the price more if he could, saying that as a CEO it is his duty to increase the value of his company for shareholders.

Before his Twitter account was shut down because of his repeated harassment of freelance reporter Lauren Duca, Shkreli used it to bash his critics.

"If you can afford our drugs with insurance, great. If you can't, you can have it for free," he tweeted back in December 2015. "Our system works."

"In D.C. If any politicians want to start, come at me," according to another tweet in November of the same year.

D.C. did, in a sense, come after him.

The House Oversight and Government Reform Committee held a hearing on the price increase in February 2016. The hearing also featured testimony from executives at Valeant Pharmaceuticals, which raised the price of two older heart medications by more than 500 percent.

Shkreli attended the hearing a few months after he was charged by the federal government and left Turing. He repeatedly invoked his Fifth Amendment right to self-incrimination and refused to answer questions.

Lawmakers still took the opportunity to chide Shkreli over his actions. Shkreli smirked throughout the tongue-lashing, at one point drawing the ire of Rep. Elijah Cummings of Maryland, the committee's top Democrat.

"I know you are smiling, but I am very serious, sir," Cummings said.

After leaving the hearing, Shkreli tweeted that the lawmakers were "imbeciles."

To be sure, Shkreli wasn't the only CEO to get attention for raising prices of off-patent brand-name drugs.

Mylan CEO Heather Bresch was brought before Congress last year after the company raised the price of allergy drug EpiPen to $600 for a two-pack.

Valeant Pharmaceuticals' executives also got heat from the House and Senate for raising the prices of Isuprel and Nitropress, two heart medications.

But Shkreli differed from those executives, refusing to stay away from the spotlight through Twitter or marathon livestreams where he talked about everything from stocks to the popular video game "League of Legends."

And he couldn't be kept off Twitter for long. Shkreli was believed to be tweeting from a new account called @samthemanTP, which was suspended by Twitter Friday evening.

A direct message to the account asking for comment was not returned Friday afternoon.

So, it isn't surprising that Shkreli retreated to his livestream soon after the verdict, lounging with a beer and answering questions about the events of the day.

He said he believes that he will only at a minimum get between six months to a year. Then, he would go back to running a software company or other venture.

"I still have my fortune to invest and create companies and do all that," he said. "It doesn't seem like life will change for Martin Shkreli ... basically ever."